Alzheon


Alzheon is an American clinical-stage biopharmaceutical company based in Framingham, Massachusetts. The company is developing medicines for patients suffering from Alzheimer's disease and other neurological and psychiatric disorders.

History

Alzheon was founded in July 2013 by Martin Tolar, MD, PhD, who serves as president and CEO of the organization. Alzheon completed a $10 million Series A round of financing in April 2015 and started the Phase lb bridging clinical program for ALZ-801, which was completed in July 2016.
In August 2018, Alzheon appointed former IVAX President Neil Flanzraich, JD, as Vice Chairman of Board of Directors.

Pipeline

The company's lead clinical candidate is ALZ-801 an oral small molecule inhibitor of amyloid aggregation and neurotoxicity and an optimized, oral prodrug of the active molecule tramiprosate. Originally developed by a Canadian firm formerly called Neurochem, the drug is expected to target amyloid plaques.